Your browser doesn't support javascript.
loading
Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.
Keck, Zhen-Yong; Pierce, Brian G; Lau, Patrick; Lu, Janine; Wang, Yong; Underwood, Alexander; Bull, Rowena A; Prentoe, Jannick; Velázquez-Moctezuma, Rodrigo; Walker, Melanie R; Luciani, Fabio; Guest, Johnathan D; Fauvelle, Catherine; Baumert, Thomas F; Bukh, Jens; Lloyd, Andrew R; Foung, Steven K H.
Affiliation
  • Keck ZY; Department of Pathology, Stanford University School of Medicine, Stanford, California, United States of America.
  • Pierce BG; University of Maryland Institute for Bioscience and Biotechnology Research, Rockville, Maryland, United States of America.
  • Lau P; Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, Maryland, United States of America.
  • Lu J; Department of Pathology, Stanford University School of Medicine, Stanford, California, United States of America.
  • Wang Y; Department of Pathology, Stanford University School of Medicine, Stanford, California, United States of America.
  • Underwood A; Department of Pathology, Stanford University School of Medicine, Stanford, California, United States of America.
  • Bull RA; Viral Immunology Systems Program, The Kirby Institute and School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.
  • Prentoe J; Viral Immunology Systems Program, The Kirby Institute and School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.
  • Velázquez-Moctezuma R; Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Walker MR; Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre Hospital and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Luciani F; Viral Immunology Systems Program, The Kirby Institute and School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.
  • Guest JD; Viral Immunology Systems Program, The Kirby Institute and School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.
  • Fauvelle C; University of Maryland Institute for Bioscience and Biotechnology Research, Rockville, Maryland, United States of America.
  • Baumert TF; Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, Maryland, United States of America.
  • Bukh J; Inserm U1110, Institut de Recherche sur les Maladies et Hépatiques, Strasbourg, France.
  • Lloyd AR; Université de Strasbourg, Strasbourg, France.
  • Foung SKH; Inserm U1110, Institut de Recherche sur les Maladies et Hépatiques, Strasbourg, France.
PLoS Pathog ; 15(5): e1007772, 2019 05.
Article in En | MEDLINE | ID: mdl-31100098
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Viral Hepatitis Vaccines / Drug Design / Viral Envelope Proteins / Hepatitis C / Hepacivirus / Hepatitis C Antibodies / Antibodies, Neutralizing Type of study: Observational_studies Limits: Adult / Humans / Male Language: En Journal: PLoS Pathog Year: 2019 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Viral Hepatitis Vaccines / Drug Design / Viral Envelope Proteins / Hepatitis C / Hepacivirus / Hepatitis C Antibodies / Antibodies, Neutralizing Type of study: Observational_studies Limits: Adult / Humans / Male Language: En Journal: PLoS Pathog Year: 2019 Type: Article Affiliation country: United States